Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAS 1440

Next Previous
Search
Drug Profile

TAS 1440

Alternative Names: TAS-1440

Latest Information Update: 19 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiho Pharmaceutical
  • Developer Otsuka Pharmaceutical; Taiho Pharmaceutical
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia
  • Preclinical Solid tumours

Most Recent Events

  • 04 Dec 2024 Astex Pharmaceuticals terminates a phase I trial for Acute myeloid leukaemia (Second-line therapy or greater, Combination therapy, Monotherapy), due to the changing treatment landscape, difficulty in enrolling eligible participants, and little likelihood of providing meaningful clinical benefit for the participants (PO, Capsule) (NCT04282668)
  • 27 Sep 2023 Phase-I development in Acute-myeloid-leukaemia (Combination therapy, Second-line therapy or greater) is ongoing in USA (PO, Capsule) (NCT04282668)
  • 27 Sep 2023 Phase-I development in Acute-myeloid-leukaemia(Monotherapy, Second-line therapy or greater) is ongoing in USA (PO, Capsule) (NCT04282668).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top